Daniel E. Geffken founded Danforth Advisors LLC. Currently, Mr. Geffken occupies the position of Co-Managing Director at Danforth Advisors LLC, Chief Financial Officer at GenePeeks, Inc., Chief Financial Officer of Lysosomal Therapeutics, Inc., Chief Financial Officer at Apic Bio, Inc., Chief Financial Officer at Locust Walk Acquisition Corp. and Chief Financial Officer for ProMIS Neurosciences, Inc.

He is also on the board of Windtree Therapeutics, Inc., Elicio Therapeutics, Inc. and SG DAN Holdings LLC.

Daniel E. Geffken previously occupied the position of Chief Operating Officer at Seaside Therapeutics LLC, Chief Financial Officer & Senior Vice President at Codon Devices, Inc., Principal Accounting Officer & Controller at Gelesis, Inc., Chief Financial Officer for Apellis Pharmaceuticals, Inc., Chief Financial Officer at Sideris Pharmaceuticals, Inc., Chief Financial Officer of Adhera Therapeutics, Inc., Chief Financial Officer for Cidara Therapeutics, Inc., Chief Financial Officer at Homology Medicines, Inc., Chief Financial Officer of Cabaletta Bio, Inc., Chief Financial Officer of Stealth BioTherapeutics Corp., Chief Financial Officer at Transkaryotic Therapies, Inc. and Chief Financial Officer for Novira Therapeutics, Inc.

He received an MBA from Harvard Business School and an undergraduate degree from The Wharton School of the University of Pennsylvania.